Inspire Medical Systems, Inc.
Inspire Medical Systems Reports Strong Q4 2024 Results and Provides 2025 Revenue Guidance
Summary
Inspire Medical Systems, Inc. announced preliminary unaudited results for Q4 and full year 2024, reporting a 25% increase in Q4 revenue to between $239.5 million and $239.7 million and a 28% increase for the full year to between $802.6 million and $802.8 million. The company also provided initial 2025 revenue guidance of $940 million to $955 million, a 17% to 19% increase over 2024. Organizational changes, including the appointment of a new Chief Manufacturing and Quality Officer, were made to support continued growth.
Profitelligence Alerts
Get alerts for INSP
Be first to know when Inspire Medical Systems, Inc. files with the SEC.
Filing Categories
Exhibits (2)
Advertisement
About Inspire Medical Systems, Inc.
Inspire Medical Systems, Inc. is a pioneering company focused on developing and commercializing innovative medical technology designed to treat obstructive sleep apnea (OSA). The company's flagship product, the Inspire therapy, is an implantable neurostimulation device that provides a unique and effective solution for patients who are unable to utilize traditional continuous positive airway pressure (CPAP) devices. Inspire Medical Systems significantly impacts the healthcare sector by offering a less invasive, patient-friendly alternative to surgical treatments for OSA, improving quality of life for those affected by sleep disorders. Headquartered in Minnesota, Inspire Medical Systems continues to expand its presence within the medical device market, collaborating closely with hospitals and medical professionals to enhance sleep health management globally. This company's contributions underscore a growing focus on personalized and technologically advanced approaches to medical challenges, marking its importance in the evolving landscape of healthcare solutions.
Official SEC Documents
Advertisement